Press Releases
| All Releases | ||||||
|---|---|---|---|---|---|---|
 |
Dyax Corp. Announces Participation in Upcoming Investor Events May 23, 2013 |
20.6 KB |
|
|||
|
BURLINGTON, Mass.--(BUSINESS WIRE)-- Dyax Corp. (NASDAQ: DYAX) announced today its participation in the following investor events: Deutsche Bank 38th Annual db Access Health Care Conference on Wednesday, May 29 in Boston, Massachusetts. George Migausky, Executive ... |
||||||
|
Dyax HAE Allies℠ Awards Program Launches on Second Annual Hereditary Angioedema (HAE) Day — a Global Event to Raise Awareness of HAE May 16, 2013 |
116.1 KB |
|
|||
|
New program acknowledges critical role of support for patients with rare and potentially life-threatening disease BURLINGTON, Mass.--(BUSINESS WIRE)-- To mark the second annual Hereditary Angioedema (HAE) Day, Dyax Corp. today announced the launch of HAE Allies, a new program recogn... |
||||||
|
Dyax Announces $30 Million Offering May 13, 2013 |
20.6 KB |
|
|||
|
BURLINGTON, Mass.--(BUSINESS WIRE)-- Dyax Corp. (NASDAQ: DYAX) announced today that it has priced a registered direct offering with RA Capital Management, Venrock, Federated Investors, Inc. and one other institutional investor for gross proceeds of approximately $30 million. The offering was priced at $2.30 ... |
||||||
|
Dyax Corp. to Participate in the Needham Healthcare Conference Apr 29, 2013 |
20.4 KB |
|
|||
|
BURLINGTON, Mass.--(BUSINESS WIRE)-- Dyax Corp. (NASDAQ: DYAX) announced today that the Company will participate in the Needham Healthcare Conference, being held April 30-May 1, 2013, at the Westin New York Grand Central Hotel in New York City. Gustav Christensen, President and Chief Executive Officer of... |
||||||
|
Dyax Corp. Announces First Quarter 2013 Financial Results Apr 25, 2013 |
32.5 KB |
|
|||
|
BURLINGTON, Mass.--(BUSINESS WIRE)-- Dyax Corp. (NASDAQ: DYAX) today announced financial results for the first quarter ended March 31, 2013. The Company will host a webcast and conference call at 5:00 p.m. (ET) today to review financial results and updates regarding its key value drivers - the KALBITOR® ... |
||||||
|
Dyax Corp. to Host First Quarter 2013 Earnings Call and Webcast Apr 18, 2013 |
17.0 KB |
|
|||
|
BURLINGTON, Mass.--(BUSINESS WIRE)-- Dyax Corp. (NASDAQ:DYAX) will host a webcast and conference call, including an open question and answer session, Thursday, April 25, 2013. During the call, management will discuss the Company's financial results for the first quarter ended March 31, 2013 and progress ... |
||||||
|
Dyax Corp. to Participate in the 25th Annual ROTH Conference Mar 12, 2013 |
18.1 KB |
|
|||
|
BURLINGTON, Mass.--(BUSINESS WIRE)-- Dyax Corp. (NASDAQ: DYAX) announced today that the Company will participate in the 25th Annual ROTH Conference, being held March 17-20, 2013, at the Ritz-Carlton Laguna Niguel in Dana Point, CA. Gustav Christensen, President and Chief Executive Officer of Dyax, will ... |
||||||
|
Dyax Announces Management Change Mar 8, 2013 |
17.9 KB |
|
|||
|
Ivana Magovcevic-Liebisch, Ph.D., J.D., Executive Vice President, Chief Operating Officer, to Leave the Company BURLINGTON, Mass.--(BUSINESS WIRE)-- Dyax Corp. (NASDAQ: DYAX) today announced that Ivana Magovcevic-Liebisch, Ph.D., J.D., Executive Vice President, Chief Operating Offic... |
||||||
|
Dyax Presents DX-2930 Data at the 2013 American Academy of Allergy, Asthma and Immunology Annual Meeting Feb 25, 2013 |
21.8 KB |
|
|||
|
DX-2930 is a Potent, Highly Specific, and Potentially Long-Acting Antibody Inhibitor of Plasma Kallikrein BURLINGTON, Mass.--(BUSINESS WIRE)-- Dyax Corp. (NASDAQ:DYAX) today announced results from a preclinical study of DX-2930, their internally developed, fully human monoclonal ant... |
||||||
|
Dyax Corp. to Participate in Upcoming 2013 Healthcare Conferences Feb 20, 2013 |
19.1 KB |
|
|||
|
BURLINGTON, Mass.--(BUSINESS WIRE)-- Dyax Corp. (NASDAQ: DYAX) announced today that executive management will participate in two upcoming conferences, providing a corporate update regarding the Company's key value drivers — the KALBITOR® (ecallantide) business and the angioedema portfolio, as ... |
||||||
|
Dyax Corp. Announces Fourth Quarter and Full Year 2012 Financial Results Feb 13, 2013 |
35.1 KB |
|
|||
|
BURLINGTON, Mass.--(BUSINESS WIRE)-- Dyax Corp. (NASDAQ: DYAX) today announced financial results for the fourth quarter and year ended December 31, 2012. Dyax will host a webcast and conference call at 5:00 p.m. (ET) today to review financial results and updates regarding its key value drivers - the KALBITOR®... |
||||||
|
Dyax Corp. and CVie Therapeutics Announce Partnership to Develop and Commercialize KALBITOR® (ecallantide) for Hereditary Angioedema (HAE) and Other Angioedema Indications in China, Hong Kong and Macau Feb 7, 2013 |
23.6 KB |
|
|||
|
BURLINGTON, Mass. & HONG KONG--(BUSINESS WIRE)-- Dyax Corp. (NASDAQ: DYAX), a developer of novel biotherapeutics for unmet medical needs, and CVie Therapeutics (CVie), a subsidiary of Lee's Pharmaceutical Holdings Ltd., announced today a strategic partnership for the development and commercialization of ... |
||||||
|
Dyax Corp. to Participate in the Leerink Swann Global Healthcare Conference Feb 6, 2013 |
18.1 KB |
|
|||
|
BURLINGTON, Mass.--(BUSINESS WIRE)-- Dyax Corp. (NASDAQ: DYAX) announced today that executive management will participate in the Leerink Swann Global Healthcare Conference, being held February 13-14, 2013, at the Waldorf Astoria in New York City. Gustav Christensen, President and Chief Executive Officer ... |
||||||
|
Dyax Corp. to Host Fourth Quarter and Year End 2012 Earnings Call and Webcast Feb 5, 2013 |
19.3 KB |
|
|||
|
BURLINGTON, Mass.--(BUSINESS WIRE)-- Dyax Corp. (NASDAQ:DYAX) will host a webcast and conference call, including an open question and answer session, Wednesday, February 13, 2013. During the call, management will discuss the Company's financial results for the fourth quarter and the year ended December 3... |
||||||
|
Dyax Corp. and Novellus Biopharma AG Announce Partnership to Develop and Commercialize KALBITOR® (ecallantide) for Hereditary Angioedema (HAE) and Other Angioedema Indications in Latin America Jan 31, 2013 |
21.9 KB |
|
|||
|
BURLINGTON, Mass. & BOGOTA, Colombia--(BUSINESS WIRE)-- Dyax Corp. (NASDAQ: DYAX), a developer of novel biotherapeutics for unmet medical needs, and Novellus Biopharma AG (Novellus) announced today a strategic partnership for the development and commercialization of KALBITOR® (ecallantide) for the t... |
||||||
|
Dyax Corp. Announces Presentation of KALBITOR® (ecallantide) Pediatric and Abdominal Attack Data at the American College of Allergy, Asthma and Immunology Annual Meeting (ACAAI) Nov 13, 2012 |
27.7 KB |
|
|||
|
BURLINGTON, Mass.--(BUSINESS WIRE)-- Dyax Corp. (NASDAQ: DYAX) announced today that two poster presentations featuring updated KALBITOR® (ecallantide) data in pediatric patients with hereditary angioedema (HAE) and HAE patients with abdominal attacks were presented at the American College of Allergy... |
||||||
|
Dyax Corp. to Participate in November 2012 Healthcare Conferences Nov 7, 2012 |
18.3 KB |
|
|||
|
BURLINGTON, Mass.--(BUSINESS WIRE)-- Dyax Corp. (NASDAQ: DYAX) announced today that executive management will participate in two upcoming conferences. Gustav Christensen, President and Chief Executive Officer of Dyax, will present on Wednesday, November 14 at 11:20 AM (GMT), at the Jeffer... |
||||||
|
Dyax Corp. Announces Third Quarter 2012 Financial Results Oct 24, 2012 |
34.9 KB |
|
|||
|
BURLINGTON, Mass.--(BUSINESS WIRE)-- Dyax Corp. (NASDAQ: DYAX) today announced financial results for the third quarter ended September 30, 2012. Dyax will host a webcast and conference call at 5:00 p.m. (ET) today to review financial results and provide updates regarding its key value drivers — the KALBITOR... |
||||||
|
Dyax Corp. to Host Third Quarter 2012 Earnings Call and Webcast Oct 17, 2012 |
18.8 KB |
|
|||
|
BURLINGTON, Mass.--(BUSINESS WIRE)-- Dyax Corp. (NASDAQ: DYAX) will host a webcast and conference call, including an open question and answer session, Wednesday, October 24, 2012. During the call, management will discuss the Company's financial results for the third quarter ending September 30, 2012 and ... |
||||||
|
Dyax Corp. Appoints Marc Kozin to Board of Directors Oct 16, 2012 |
19.8 KB |
|
|||
|
BURLINGTON, Mass.--(BUSINESS WIRE)-- Dyax Corp. (NASDAQ: DYAX), a developer of novel biotherapeutics for unmet medical needs, announced today the appointment of Marc Kozin to its Board of Directors. "Marc brings to our Board nearly 30 years of domestic and international experience in stra... |
||||||
|
||||||
= add release to Briefcase
0.01 (-0.38)%
Briefcase
Email Alerts
IR Contacts
RSS Feeds
Mobile Investor